Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...
Pharmabiz2d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
The Pharma Letter3d
Santhera partners with Clinigen to expand Agamree access
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
Santhera Pharmaceuticals Holding AG: Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...
pharmaphorum6d
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Insider Monkey17d
Is Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024?
Additionally, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) launched Agamree (vamorolone) in 2024, an oral suspension for Duchenne Muscular Dystrophy (DMD), achieving strong initial commercial success.
central.newschannelnebraska20d
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National Medical ...
FOX 40 WICZ TV20d
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National ...
SNN TV20d
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National ...